Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 400 of 517 entries
View as:

A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03121716 Org: User:
Start: 04/26/17 End: 07/31/20 Due: 07/31/21

Drug-Drug Interaction of SHR1459 With a Strong CYP3A Index Inducer (Rifampicin)

Phase: N/A Priority: Normal
NCT ID: NCT04649723 Org: User:
Start: 11/24/20 End: 12/14/20 Due: 12/14/21

Study on the Food Effects of Oral SHR4640 Tablets in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT04620408 Org: User:
Start: 12/31/20 End: 02/28/21 Due: 02/28/22

A Trial of SHR-1703 in Asthma

Phase: N/A Priority: Normal
NCT ID: NCT05042401 Org: User:
Start: 10/12/21 End: 06/15/23 Due: 06/15/24

Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04426955 Org: User:
Start: 06/30/20 End: 12/31/23 Due: 12/31/24

Hetrombopag for Pediatric Patients With Chronic Immune Thrombocytopenia

Phase: N/A Priority: Normal
NCT ID: NCT04737850 Org: User:
Start: 03/29/21 End: 05/31/25 Due: 05/31/26

A Relative Bioavailability Study of Different Processes of SHR2554 Tablets in Healthy Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT05049083 Org: User:
Start: 12/17/21 End: 04/29/22 Due: 04/29/23

Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05473624 Org: User:
Start: 08/23/22 End: 12/31/26 Due: 12/31/27

Safety and Pharmacokinetics/Pharmacodynamics of SHR3824 in Type 2 Diabetes Patients With Renal Insufficient

Phase: N/A Priority: Normal
NCT ID: NCT03159832 Org: User:
Start: 06/30/15 End: 12/31/17 Due: 12/31/18

Study of Remimazolam Tosilate in Patients Undergoing Diagnostic Upper GI Endoscopy

Phase: N/A Priority: Normal
NCT ID: NCT03425474 Org: User:
Start: 09/01/17 End: 11/10/17 Due: 11/10/18

A Trial of SHR-1703 in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT04480762 Org: User:
Start: 08/04/20 End: 09/21/21 Due: 09/21/22

Multi-dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DDO-3055 Tablets in Healthy Subjects.

Phase: N/A Priority: Normal
NCT ID: NCT04775615 Org: User:
Start: 03/17/21 End: 06/01/21 Due: 06/01/22

Multi-dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DDO-3055 Tablets in Patients With Anemia of Non-dialysis Chronic Kidney Diseases.

Phase: N/A Priority: Normal
NCT ID: NCT04470063 Org: User:
Start: 11/17/20 End: 12/31/21 Due: 12/31/22

Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT05363800 Org: User:
Start: 06/17/22 End: 12/30/24 Due: 12/30/25

A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04679038 Org: User:
Start: 03/17/21 End: 10/01/23 Due: 10/01/24

A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane

Phase: N/A Priority: Normal
NCT ID: NCT05424835 Org: User:
Start: 08/04/22 End: 12/31/27 Due: 12/31/28

A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT06368167 Org: User:
Start: 04/30/24 End: 04/30/27 Due: 04/30/28

Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04108676 Org: User:
Start: 09/07/19 End: 11/18/19 Due: 11/18/20

To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Oral Antidiabetic Drugs

Phase: N/A Priority: Normal
NCT ID: NCT05699408 Org: User:
Start: 03/31/23 End: 11/23/24 Due: 11/23/25

Safety and Tolerability of SHR-1316 in Subjects With Advanced Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03474289 Org: User:
Start: 03/01/18 End: 10/31/19 Due: 10/31/20

Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Phase: N/A Priority: Normal
NCT ID: NCT05942001 Org: User:
Start: 08/03/23 End: 08/31/25 Due: 08/31/26

A Study to Evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole in Subjects With Recurrent Vulvovaginal Candidiasis

Phase: N/A Priority: Normal
NCT ID: NCT05074602 Org: User:
Start: 09/14/21 End: 09/30/23 Due: 09/30/24

A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout

Phase: N/A Priority: Normal
NCT ID: NCT04956432 Org: User:
Start: 06/15/21 End: 08/23/24 Due: 08/23/25

Pharmacokinetics and Safety of SHR0302 in Patients With Hepatic Impairment

Phase: N/A Priority: Normal
NCT ID: NCT04293029 Org: User:
Start: 05/20/20 End: 12/30/20 Due: 12/30/21

Effect of Rifampicin on the Pharmacokinetics of Apatinib

Phase: N/A Priority: Normal
NCT ID: NCT02836821 Org: User:
Start: 05/31/16 End: 02/28/17 Due: 02/28/18